Navigation Links
DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
Date:11/23/2009

CUPERTINO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, and Joe Stauffer, Chief Medical Officer, will be presenting at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1 at 3:30 pm Eastern Time. The conference is being held at the New York Palace Hotel in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

To access the live presentation via the internet, please go to the direct conference link at:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=DRRX&item_id=2539284 or to the DURECT Investor Relations tab at www.durect.com.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective ow
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
2. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
3. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
4. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
5. Beckman Coulter to Present at the 2009 Piper Jaffray Healthcare Conference
6. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
7. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
8. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
9. Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference
10. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Perrigo Company To Present at the Sidoti Emerging Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... SAN JOSE, Calif. , June 19, 2013 ... (NYSE: BDX ), a leading global medical technology ... X-20 Cell Analyzer , the latest in its line of ... X-20 Cell Analyzer delivers high-performance multicolor analysis with the most ... (76.2 X 73.7 cm) and a height of 30" (76.2 ...
(Date:6/19/2013)... PLAINS, N.Y. , June 19, 2013  This ... supporting more than 300 research projects with one goal ... And in 2013, "Team In Training" (TNT), a flagship ... endurance sports training program, is marking its landmark 25 ... invest more than $875 million in research to discover ...
(Date:6/19/2013)... June 19, 2013 Today MedeAnalytics, a ... the next-generation of its Employer Group and ... plans to provide their employer groups an intuitive ... medical and prescription drug claims, network utilization, and ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group and ...
Breaking Medicine Technology:New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
(Date:6/19/2013)... Kaanapali, HI (PRWEB) June 19, 2013 ... new office located at The Wailea Town Center providing ... real estate brokerage. Ken Harris, a licensed Hawaii ... in 2008 and is the principal broker. , ... south Maui, the Wailea resort area offers spectacular scenery, ...
(Date:6/19/2013)... The deadline to enter min’s ... June 21 at midnight ET. This industry-known awards ... people who’ve raised the bar on magazine marketing ... . , Any consumer and b2b publishing company ... to enter. Additionally, advertising agencies and corporations are ...
(Date:6/19/2013)... Chrysler made news recently when it refused to accept ... The Jeep models in question are the 1993-2004 Jeep Grand ... NHTSA are vulnerable to fire and explosion in a crash. ... and have been alleged to catch fire or explode upon ... 32 rear-end crashes, which resulted in 44 deaths and the ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...
(Date:6/19/2013)... led by researchers at The University of Texas MD ... show remarkable promise for the treatment of relapsed or ... interim findings of the 18-center Phase 2 study were ... Medicine . Previous interim findings were presented in December ... Meeting and Exposition. , Unprecedented results, fewer ...
Breaking Medicine News(10 mins):Health News:Harris Hawaii Realtor Group Opens New Office in Wailea, HI 2Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... wonder fish medicine for asthma patients began here Thursday amid ... of people were seen standing in queues for their turn ... offering by Bathini Goud family to avoid any controversy. ... cure for asthma, began at 3.42 p.m., the time fixed ...
... Intel has decided to extend its innovation beyond manufacturing ... to team up with other medical and healthcare companies’ ... and seven others have joined hands to enable high-end ... Health Alliance, led by Intel will seek to effectively ...
... longest working hours in Europe - a reason that is ... study //. ,Stress expert Cary Cooper, of Lancaster University, ... their negative effect on men's health, particularly those working in ... of the Daily Mail. ,Researchers studied 2,200 men ...
... be now treated by a new approach involving release ... with mice by scientists // at John Hopkins Institute ... Medicine. ,The discovery by researchers in Hopkins' ... Genetic Medicine reveals that a protein called GCN5 is ...
... common BP medication during first trimester of pregnancy have ... The Food and Drug Administration reports from data collected ... ,The study, led by William Cooper, M.D., M.P.H., associate ... Hospital at Vanderbilt, found infants born to mothers who ...
... Rajasthan man who has pledged not to marry till he passes ... a wife. He has failed in the examination yet again! // ... Behror town, over 140 km from here, has been taking the ... years of his life, he vowed to marry only after getting ...
Cached Medicine News:Health News:Administration of Fish Drug for Asthma Patients Begins in Andhra 2Health News:Diabetes - New Treatment Approach At John Hopkins 2Health News:Birth Defects Link With ACE Inhibitor Use, FDA Reports 2
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: